Repros Therapeutics, Inc. (RPRX)

[docbanker]

One is me.
Here is how I see it:
This stock fell to $4 on the NOT APPROVABLE decision. They had over $3 in cash at that point. Now the stock is $8 and they have less than $3 in cash, pro forma for Oct-Feb burn and a more reasonable payables #. How are they not going to have to do more trials if ENCY, in the same position as them (said no new trials, FDA said yes to new trials and FDA WON), got an APPROVABLE LETTER and still lost and had to do new trials. Other stuff is preclin. EMIS, FLML and other "formulations" people have had no success. I think it goes to $2 in a year or so. Plus no smart healthcare institutional money in this, except Orbimed but theyve been pretty shaky lately.